Frazier Life Sciences Public Fund, L.P. - 23 Sep 2021 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: 10%+ Owner
Issuer ticker: VRDN
Reported as of: 23 Sep 2021
Net transaction value: +$2,200,000
SEC form: 4
Accepted by SEC: 28 Sep 2021, 19:46:45 UTC
Prior SEC filing: 26 Aug 2021
Next SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: Frazier Life Sciences Public Fund L.P., By: FHMLSP, L.P., its General Partner. By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer

Key filing fact

Frazier Life Sciences Public Fund, L.P. filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 28 Sep 2021.

Key facts

This page summarizes Frazier Life Sciences Public Fund, L.P.'s Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Sep 2021, 19:46.

Change

Previous filing in this sequence was filed on 26 Aug 2021.
Current net transaction value: +$2,200,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Purchase

Transaction value: $2,200,000
Shares: +200,000
Change %: +15%
Price: $11.00
Shares after: 1,505,200
Date: 23 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frazier Life Sciences Public Fund, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any.